Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
AstraZeneca
Medtronic
Express Scripts
Johnson and Johnson

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

ABBVIE INC Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for ABBVIE INC
International Patents:1176
US Patents:62
Tradenames:13
Ingredients:13
NDAs:14
Drug Master File Entries: 15
Patent Litigation for ABBVIE INC: See patent lawsuits for ABBVIE INC

Drugs and US Patents for ABBVIE INC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 DISCN Yes No 7,364,752*PED ⤷  Free Forever Trial ⤷  Free Forever Trial
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir, paritaprevir, ritonavir TABLET;ORAL 206619-001 Dec 19, 2014 DISCN Yes No 9,629,841 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes 9,321,807*PED ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Abbvie Inc RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-001 Aug 16, 2019 RX Yes Yes 9,951,080 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No 9,539,251 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ABBVIE INC

Paragraph IV (Patent) Challenges for ABBVIE INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19

International Patents for ABBVIE INC Drugs

Country Patent Number Estimated Expiration
European Patent Office 2628481 ⤷  Free Forever Trial
Japan 2018162265 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2006091529 ⤷  Free Forever Trial
China 111163779 ⤷  Free Forever Trial
Malaysia 159820 ⤷  Free Forever Trial
Mexico 2013006951 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for ABBVIE INC Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506716 2090010-6 Sweden ⤷  Free Forever Trial PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1404 20191218
2692346 122017000074 Germany ⤷  Free Forever Trial PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2203431 38/2015 Austria ⤷  Free Forever Trial PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115
2506716 2020006 Norway ⤷  Free Forever Trial PRODUCT NAME: UPADACITINIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/19/1404 20200103
2368890 300731 Netherlands ⤷  Free Forever Trial PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2340029 PA2015011 Lithuania ⤷  Free Forever Trial PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Express Scripts
Boehringer Ingelheim
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.